Jia Chen, PhD, is head of clinical pharmacology at Simcere Zaiming responsible for clinical pharmacology, pharmacometrics and bioanalysis to the overall company portfolio. Jia has decades of years experiences in the pharmaceutical industry focusing on the clinical pharmacology and drug development. His PhD scholar was obtained from Clinical Pharmacology Research Center in Peking Union Medical College Hospital and his mentor was Prof. Pei Hu. During his PhD, he is systemically trained for pharmacokinetics, clinical pharmacology and modelling and simulation. In 2015-2017, Jia was a fellow under the Division of Quantitative Methods and Modelling in ORS/OGD/CDER/FDA and most of his work focused on generic drug evaluation and guidance development using modelling and simulation. 2017 Jia joined Novartis in China. He participated many oncology programs focusing on China development and NDA/BLA preparation. He was also global clinpharm representative to lead the compound development in pre-clinical and early clinical stage such as EED inhibitor, NSD2 inhibitor, YAP/TEAD protein-protein interaction inhibitor and topical products of JAK inhibitor. After his experience in Novartis, Jia was the clinpharm therapeutic head of hematology at Janssen china R&D, responsible for developing and implementing product-based China clinical pharmacological and quantitative pharmacological strategies, recommending the right dosages for Chinese patients. In addition, he also involved in Asian-led indication development for a solid tumor product and clinpharm development strategies in China for some products in other disease areas such as ophthalmology. In 2022, Jia joined Simcere and Simcere Zaiming, he is currently responsible for the pharmacometrics strategies for the whole drug development life-span from preclinical to clinical and clinpharm/bioanalysis strategies for the drug entering clinical development. His experience covered different drug modalities such as small molecule, monoclone antibody, bi/tri-specific antibody, antibody-drug conjugates and protac etc.) He also supports the clinpharm development strategy of cell therapies in Simnova.
Jia currently is the committee member of DIA clinical pharmacology society.
博士，现担任先声再明医药有限公司临床药理负责人，高级总监，负责公司管线的临床药理，定量药理学和临床生物分析。陈博士具有多年的全球药物开发/发现临床药理行业经验。陈博士于2015年毕业于北京协和医院临床药理研究中心，师从于胡蓓教授，系统地学习和研究了药代动力学，临床药理学和建模与模拟。2015-2017年间前往美国FDA，在DQMM/ORS/OGD部门进修，主要关注于运用模型和仿真的技术支持BE研究的审评和指导原则的开发。2017年回国后加入诺华，参与多个抗肿瘤药物的中国开发策略和药物上市关键报批材料的设计和准备。曾作为全球临床药理的代表参与到多个抗肿瘤药物，包括EED抑制剂、NSD2抑制剂、YAP/TEAD蛋白相互作用抑制剂，和一个治疗特异性皮炎的JAK抑制剂的皮肤制剂的临床前和临床开发工作。之后加入强生，担任中国临床药理部门血液学TA负责人，负责产品在中国的临床药理策略。也参与其他疾病领域，如实体瘤产品的亚太特异性适应症、眼科等产品的中国研发策略的讨论。2022年加入先声和先声再明，作为先声再明临床药理负责人，支持公司全管线从药物筛选至临床开发中的定量药理学策略、进行临床后的临床药理学策略和定量药理学策略的开发制定、和生物分析方法的开发，涉及多个分子类型（小分子、单抗、双/三特异性抗体、ADC、Protac等）。同时支持先博生物（先声子公司）的细胞治疗产品的临床药理学开发策略。陈嘉博士目前为DIA临床药理社区核心工作组成员。